Update shared on 05 Sep 2025
As both net profit margin and revenue growth forecasts for Alembic Pharmaceuticals remain stable, the consensus analyst price target is unchanged at ₹1057.
What's in the News
- Alembic Pharmaceuticals received USFDA final approval for Macitentan Tablets, 10 mg, a generic of Opsumit, targeting a USD 1,180 million market.
- USFDA granted final approval to Alembic for Tretinoin Cream USP, 0.025%, a generic of Retin-A Cream, with an estimated USD 94 million market.
- Alembic obtained USFDA final approval for Carbamazepine Extended-Release Tablets USP (100 mg, 200 mg, 400 mg), a generic of Tegretol-XR.
- Mr. G. Krishnan was appointed CFO, replacing Mr. R. K. Baheti, who remains Executive Director.
- Board meeting scheduled to consider and approve unaudited financial results for the quarter ended June 2025.
Valuation Changes
Summary of Valuation Changes for Alembic Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1057.
- The Net Profit Margin for Alembic Pharmaceuticals remained effectively unchanged, at 12.54%.
- The Consensus Revenue Growth forecasts for Alembic Pharmaceuticals remained effectively unchanged, at 10.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.